Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Ureña-Torres, Pablo; Prié, Dominique; Keddad, Karim; Preston, Peter; Wilde, Paul; Wan, Hong; Copley, J Brian

Ureña-Torres, Pablo; Prié, Dominique; Keddad, Karim; Preston, Peter; Wilde, Paul; Wan, Hong; Copley, J Brian.

Affiliation

Ureña-Torres P; Service de Néphrologie-Dialyse, Clinique du Landy, Paris, France. urena.pablo@wanadoo.fr.

BMC Nephrol ; 15: 71, 2014 May 05.

Article in En | MEDLINE | ID: mdl-24885942

Subject(s)

Fibroblast Growth Factors/blood; Lanthanum/therapeutic use; Phosphorus/blood; Renal Insufficiency, Chronic/blood; Renal Insufficiency, Chronic/drug therapy; Adult; Aged; Aged, 80 and over; Biomarkers/blood; Double-Blind Method; Female; Fibroblast Growth Factor-23; Humans; Male; Middle Aged; Placebo Effect; Reference Values; Renal Insufficiency, Chronic/diagnosis; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phosphorus / Renal Insufficiency, Chronic / Fibroblast Growth Factors / Lanthanum Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: BMC Nephrol Journal subject: NEFROLOGIA Year: 2014 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google